This startup develops Messenger RNA (mRNA) drug delivery systems and discovers new mRNA-based therapies. Their technology specifically targets liver cells, enabling the development of treatments for various diseases affecting the liver, spleen, lungs, and brain.
Funding
Funding not disclosed
Founders
Product
Problem
The development of effective mRNA-based therapies is hindered by the challenge of delivering mRNA molecules specifically and efficiently to target cells and tissues within the body. Traditional delivery methods often lack precision, leading to off-target effects and limited therapeutic efficacy, particularly for diseases affecting specific organs.
Solution
Xinghe Disai Biotech is developing lipid nanoparticle (LNP) delivery systems for mRNA therapeutics, focusing on targeted delivery to specific tissues. Their proprietary LNP technology enables the development of novel mRNA drugs with improved efficacy and reduced side effects. The company is building a library of LNP delivery systems and developing mRNA drugs to address unmet clinical needs. Their technology platform aims to create differentiated mRNA product pipelines with high technical barriers to entry.
Target Audience
The primary target audience includes pharmaceutical companies, research institutions, and clinical partners seeking advanced mRNA delivery solutions and novel mRNA-based therapeutics.
Features
- Proprietary LNP delivery system for targeted mRNA delivery
- Focus on mRNA drug development for diseases with high unmet clinical need
- Technology platform for creating differentiated mRNA product pipelines
- LNP library construction for diverse therapeutic applications